Literature DB >> 33600480

Risk factors and visual outcome of Non-Arteritic Ischemic Optic Neuropathy (NAION): Experience of a tertiary center in Kuwait.

Raed Behbehani1, Abdullah Ali1, Ashref Al-Moosa1.   

Abstract

BACKGROUND: Non-arteritic ischemic optic neuropathy (NAION) is the most common acute optic neuropathy over the age of 50 years. NAION is commonly associated with systemic vascular risk factors (diabetes, hypertension, hyperlipidemia) and small cup-to-disc-ratio. We have assessed the prevalence risk factors of NAION and the visual outcome in patients referred to a tertiary ophthalmology center in Kuwait.
MATERIALS AND METHODS: A retrospective review of new cases of NAION presenting within 2 weeks of onset were included and baseline clinical and demographics characteristic were determined. The prevalence of risk factors and the visual outcome (change in logMAR visual acuity, mean deviation of visual field) was compared between young NAION patients (below 50 years of age) and older NAION patients (over 50 years of age). The odds ratio of a final favorable visual outcome (visual acuity 20/40 or better) by age category was determined.
RESULTS: Seventy-eight eyes of 78 patients with recent onset NAION were included in the study. The most prevalent risk factors for NAION in our subjects were diabetes (64.1%), small cup-to-disc ratio (61.5%), hyperlipidemia (51.3%) and hypertension (38.5%). Young NAION patients had better final logMAR visual acuity (0.55 +- 0.57) then older NAION patients (0.9 +- 0.73), (p = 0.03). Furthermore, young NAION patients were 2.8 times more likely to have a final visual acuity of 20/40 or better than older NAION patients, odds ratio (OR), 2.87; 95% confidence interval (CI), 1.12-7.40, Chi-square p-value = 0.03).
CONCLUSION: There is a high prevalence of systemic vascular risk factors and small cup-to-disc ratio in NAION patients referred to our center across different age groups (below and above 50 years). Patients below the age of 50 years with NAION are more likely to have a final visual acuity of 20/40 or better than NAION patients above the age of 50 years.

Entities:  

Year:  2021        PMID: 33600480      PMCID: PMC7891726          DOI: 10.1371/journal.pone.0247126

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  19 in total

1.  The natural history of non-arteritic anterior ischaemic optic neuropathy.

Authors:  G V Sawle; C B James; R W Russell
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-10       Impact factor: 10.154

2.  Structure-Function Analysis of Nonarteritic Anterior Ischemic Optic Neuropathy and Age-Related Differences in Outcome.

Authors:  Ming-Hui Sun; Yaping Joyce Liao
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

3.  Comparison of Visual Outcomes of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients with and without Diabetes Mellitus.

Authors:  Srilakshmi Sharma; Sarah Kwan; Katherine A Fallano; Jiangxia Wang; Neil R Miller; Prem S Subramanian
Journal:  Ophthalmology       Date:  2016-12-22       Impact factor: 12.079

4.  Young Adults with Anterior Ischemic Optic Neuropathy: A Multicenter Optic Disc Drusen Study.

Authors:  Steffen Hamann; Lasse Malmqvist; Marianne Wegener; Valérie Biousse; Lulu Bursztyn; Gülsenay Citirak; Fiona Costello; Alison V Crum; Kathleen Digre; Masoud Aghsaei Fard; J Alexander Fraser; Ruth Huna-Baron; Bradley Katz; Mitchell Lawlor; Nancy J Newman; Jason H Peragallo; Axel Petzold; Patrick A Sibony; Prem S Subramanian; Judith Ea Warner; Sui H Wong; Clare L Fraser
Journal:  Am J Ophthalmol       Date:  2020-04-13       Impact factor: 5.258

5.  Anterior ischemic optic neuropathy in patients younger than 50 years.

Authors:  Pisit Preechawat; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Am J Ophthalmol       Date:  2007-09-14       Impact factor: 5.258

6.  Ischemic optic neuropathy as the first manifestation of elevated cholesterol levels in young patients.

Authors:  Vincent A Deramo; Robert C Sergott; James J Augsburger; Rod Foroozan; Peter J Savino; Anthony Leone
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

7.  Nonarteritic anterior ischemic optic neuropathy and tobacco smoking.

Authors:  Sohan Singh Hayreh; Jost B Jonas; M Bridget Zimmerman
Journal:  Ophthalmology       Date:  2007-04       Impact factor: 12.079

8.  Non-arteritic anterior ischaemic optic neuropathy is nearly systematically associated with obstructive sleep apnoea.

Authors:  K Palombi; E Renard; P Levy; C Chiquet; Ch Deschaux; J P Romanet; J L Pépin
Journal:  Br J Ophthalmol       Date:  2006-03-23       Impact factor: 4.638

9.  Outcomes of optic nerve sheath decompression for nonarteritic ischemic optic neuropathy.

Authors:  R D Yee; A K Selky; V A Purvin
Journal:  J Neuroophthalmol       Date:  1994-06       Impact factor: 3.042

10.  The morphology of an infarct in nonarteritic anterior ischemic optic neuropathy.

Authors:  Rachel A Tesser; Eric R Niendorf; Leonard A Levin
Journal:  Ophthalmology       Date:  2003-10       Impact factor: 12.079

View more
  4 in total

1.  Risk of Ocular Adverse Events With Taxane-Based Chemotherapy.

Authors:  Mohit Sodhi; Sonia N Yeung; David Maberley; Frederick Mikelberg; Mahyar Etminan
Journal:  JAMA Ophthalmol       Date:  2022-09-01       Impact factor: 8.253

2.  Epidemiology of postoperative visual loss for non-ocular surgery in a cohort of inpatients.

Authors:  John C Lin; Dustin D French; Curtis E Margo; Paul B Greenberg
Journal:  Eye (Lond)       Date:  2021-11-19       Impact factor: 4.456

3.  The Protective Effects of n-Butylidenephthalide on Retinal Ganglion Cells during Ischemic Injury.

Authors:  Yu-Yau Chou; Jia-Ying Chien; Jhih-Wei Ciou; Shun-Ping Huang
Journal:  Int J Mol Sci       Date:  2022-02-14       Impact factor: 5.923

4.  Factors Associated With Visual Acuity in Non-arteritic Ischemic Optic Neuropathy Patients: A Five-Year Cross-Sectional Study.

Authors:  Parinee Kemchoknatee; Chotika Singhakul; Duanghathai Tangon; Thansit Srisombut
Journal:  Cureus       Date:  2022-09-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.